Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company with a market capitalization of $240 million, recently reported that its Chief Scientific Officer, Carter Todd Alfred, sold 5,413 ...

Adial Pharmaceuticals (ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United States Patent and Trademark ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have invented an oral formulation of ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application (IND ...

Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...

Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...

New Patent expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.